Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has completed acquisition of the US license rights to the Nucynta franchise from Janssen Pharmaceuticals for $1.05bn.
Subscribe to our email newsletter
Nucynta is indicated to manage moderate-to-severe acute pain in adults, Nucynta ER extended release tablets are indicated to manage pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment.
Nucynta oral solution is an approved oral form of tapentadol that has not been launched.
The franchise includes Nucynta (tapentadol), Nucynta ER (tapentadol) extended-release tablets and Nucynta (tapentadol) oral solution.
Depomed assumed the US commercialization rights and related royalty obligations for Nucynta to German pharmaceutical firm Grunenthal, the originator of tapentadol.
Janssen will retain license rights for these products in Canada, Japan and a number of other countries outside the US.
Depomed plans to re-launch Nucynta and Nucynta ER in June 2015 with an improved focus on the molecule’s dual mechanism of action, and on Nucynta ER’s approved indications based on studies in both nociceptive and neuropathic pain states.
The contract sales organization, Quintiles, which promoted the Nucynta franchise for Janssen, will continue to support these products for Depomed from now until re-launch in June.